These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 34121564

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
    Zhen S, Takahashi Y, Narita S, Yang YC, Li X.
    Oncotarget; 2017 Feb 07; 8(6):9375-9387. PubMed ID: 28030843
    [Abstract] [Full Text] [Related]

  • 23. Oligonucleotide-functionalized hydrogels for sustained release of small molecule (aptamer) therapeutics.
    Agrawal NK, Allen P, Song YH, Wachs RA, Du Y, Ellington AD, Schmidt CE.
    Acta Biomater; 2020 Jan 15; 102():315-325. PubMed ID: 31760222
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
    Yan B, Chen Q, Shimada K, Tang M, Li H, Gurumurthy A, Khoury JD, Xu B, Huang S, Qiu Y.
    Leukemia; 2019 Apr 15; 33(4):931-944. PubMed ID: 30291336
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. CD123-targeted therapy in acute myeloid leukemia.
    Espinoza-Gutarra MR, Green SD, Zeidner JF, Konig H.
    Expert Rev Hematol; 2021 Jun 15; 14(6):561-576. PubMed ID: 34043467
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
    Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, Braley H, Panousis C, Roberts AW, He SZ, Thomas D, Fabri L, Vairo G, Lock RB, Lopez AF, Nash AD.
    Leukemia; 2014 Nov 15; 28(11):2213-21. PubMed ID: 24705479
    [Abstract] [Full Text] [Related]

  • 32. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
    Sun S, Zou H, Li L, Liu Q, Ding N, Zeng L, Li H, Mao S.
    Int J Pharm; 2019 Sep 10; 568():118518. PubMed ID: 31319147
    [Abstract] [Full Text] [Related]

  • 33. Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation.
    Vaidya A, Doherty E, Wu X, Huang S, Hebbar N, Thanekar U, Bonifant CL, Cheng C, Gottschalk S, Velasquez MP.
    Haematologica; 2023 Apr 01; 108(4):1039-1052. PubMed ID: 35899386
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of Vγ9Vδ2 T cells.
    Zhang X, Ang WX, Du Z, Ng YY, Zha S, Chen C, Xiao L, Ng JY, Chng WJ, Wang S.
    Immunotherapy; 2022 Apr 01; 14(5):321-336. PubMed ID: 35152722
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.